OBJECTIVE: The objective was to compare cancer risk in a RA cohort population treated with TNF antagonists, and identify the characteristics of the patients at higher risk. METHODS: The study involved 1114 RA patients treated with anti-TNF agents after failing to respond to traditional DMARDs, 1064 of whom were evaluable for adverse events over an average observational period of 23.32 months. The relative cancer risks (expressed as hazard ratios) in the anti-TNF treated patients were estimated using univariate and multivariate analyses. The rate of cancer in this cohort was compared with that in the general population using data from the Varese and Milan Cancer Report. RESULTS: There were 18 incident cases (1.7%), 4 of which involved lymphomas. Comparison with the general population showed that the overall cancer risk was similar, but the risk of lymphoma was about five times higher in the RA patients treated with a biological agent. Higher RR were found in males (HR 4.95, 95% CI 1.97-12.48; p=0.001) and patients aged >65 years (HR 2.72, 95% CI 1.08-6.84; p=0.034); combined therapy with methotrexate seemed to be protective (HR 0.31, 95% CI 0.11-0.87; p=0.026). CONCLUSION: The overall cancer risk in RA patients treated with anti-TNF seemed to be similar to that in the general population in the same geographical area, but the risk of haematological cancer was significantly greater. The demographic and clinical factors associated with a higher risk of cancer in our cohort were male gender and an age of >65 years. Copyright 2009 Elsevier B.V. All rights reserved.
OBJECTIVE: The objective was to compare cancer risk in a RA cohort population treated with TNF antagonists, and identify the characteristics of the patients at higher risk. METHODS: The study involved 1114 RApatients treated with anti-TNF agents after failing to respond to traditional DMARDs, 1064 of whom were evaluable for adverse events over an average observational period of 23.32 months. The relative cancer risks (expressed as hazard ratios) in the anti-TNF treated patients were estimated using univariate and multivariate analyses. The rate of cancer in this cohort was compared with that in the general population using data from the Varese and Milan Cancer Report. RESULTS: There were 18 incident cases (1.7%), 4 of which involved lymphomas. Comparison with the general population showed that the overall cancer risk was similar, but the risk of lymphoma was about five times higher in the RApatients treated with a biological agent. Higher RR were found in males (HR 4.95, 95% CI 1.97-12.48; p=0.001) and patients aged >65 years (HR 2.72, 95% CI 1.08-6.84; p=0.034); combined therapy with methotrexate seemed to be protective (HR 0.31, 95% CI 0.11-0.87; p=0.026). CONCLUSION: The overall cancer risk in RApatients treated with anti-TNF seemed to be similar to that in the general population in the same geographical area, but the risk of haematological cancer was significantly greater. The demographic and clinical factors associated with a higher risk of cancer in our cohort were male gender and an age of >65 years. Copyright 2009 Elsevier B.V. All rights reserved.
Authors: Maria Estela Martinez-Escala; Alba L Posligua; Heather Wickless; Audrey Rutherford; Kimberly A Sable; Belen Rubio-Gonzalez; Xiaolong A Zhou; Jason B Kaplan; Barbara Pro; Jaehyuk Choi; Christiane Querfeld; Steven T Rosen; Joan Guitart Journal: J Am Acad Dermatol Date: 2018-01-04 Impact factor: 11.527
Authors: Marta Fantò; Mario Stefano Peragallo; Mario Pietrosanti; Roberta Di Rosa; Andrea Picchianti Diamanti; Simonetta Salemi; Raffaele D'Amelio Journal: Intern Emerg Med Date: 2015-06-23 Impact factor: 3.397
Authors: Najia Hajjaj-Hassouni; Marzooq Al-Badi; Ala' Al-Heresh; Samar Al-Emadi; Ahmed El Bawendi; Ayman El Garf; Khaled El Hadidi; Hussein Halabi; Mohammed Hammoudeh; Selma El Hassani; Mustafa Al Maaini; Ibrahim Nahar; Aïcha Ladjouze Rezig; Slaheddine Sellami; Wafaa Sweiri; Ramiz Alswailem; Beverly Traub; Imad Uthman; Elsa van Duuren; Leith Zakraoui; Bassel El Zorkany; Loreto Carmona; Maxime Dougados Journal: Clin Rheumatol Date: 2012-01-07 Impact factor: 2.980
Authors: Raja K Sivamani; Genevieve Correa; Yoko Ono; Michael P Bowen; Siba P Raychaudhuri; Emanual Maverakis Journal: Indian J Dermatol Date: 2010 Apr-Jun Impact factor: 1.494
Authors: Gregory S Calip; Pritesh R Patel; Sruthi Adimadhyam; Shan Xing; Zhaoju Wu; Karen Sweiss; Glen T Schumock; Todd A Lee; Brian C-H Chiu Journal: Int J Cancer Date: 2018-04-16 Impact factor: 7.396
Authors: Abbas K Samadi; Alan Bilsland; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Anupam Bishayee; Asfar S Azmi; Bal L Lokeshwar; Brendan Grue; Carolina Panis; Chandra S Boosani; Deepak Poudyal; Diana M Stafforini; Dipita Bhakta; Elena Niccolai; Gunjan Guha; H P Vasantha Rupasinghe; Hiromasa Fujii; Kanya Honoki; Kapil Mehta; Katia Aquilano; Leroy Lowe; Lorne J Hofseth; Luigi Ricciardiello; Maria Rosa Ciriolo; Neetu Singh; Richard L Whelan; Rupesh Chaturvedi; S Salman Ashraf; H M C Shantha Kumara; Somaira Nowsheen; Sulma I Mohammed; W Nicol Keith; William G Helferich; Xujuan Yang Journal: Semin Cancer Biol Date: 2015-05-05 Impact factor: 15.707